Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Lapatinib and breast cancer: current indications and outlook for the future.

Moreira C, Kaklamani V.

Expert Rev Anticancer Ther. 2010 Aug;10(8):1171-82. doi: 10.1586/era.10.113. Review.

PMID:
20735304
2.

Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.

Paul B, Trovato JA, Thompson J.

Am J Health Syst Pharm. 2008 Sep 15;65(18):1703-10. doi: 10.2146/ajhp070646. Review.

PMID:
18768996
3.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
4.
5.

Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

Cameron DA, Stein S.

Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Review.

PMID:
18594499
6.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

PMID:
19786658
7.

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

Ito Y, Tokudome N, Sugihara T, Takahashi S, Hatake K.

Breast Cancer. 2007;14(2):156-62. Review.

8.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D.

N Engl J Med. 2006 Dec 28;355(26):2733-43. Erratum in: N Engl J Med. 2007 Apr 5;356(14):1487.

9.

[Lapatinib treatment-option in trastuzumab-resistant breast cancer].

Pikó B.

Magy Onkol. 2009 Dec;53(4):369-75. doi: 10.1556/MOnkol.53.2009.4.6. Review. Hungarian.

10.

The emerging role of lapatinib in HER2-positive breast cancer.

Ulhoa-Cintra A, Greenberg L, Geyer CE.

Curr Oncol Rep. 2008 Jan;10(1):10-7. Review.

PMID:
18366956
11.

Lapatinib and ixabepilone for the treatment of metastatic breast cancer.

Halterman PA.

Pharmacotherapy. 2008 Oct;28(10):1255-66. doi: 10.1592/phco.28.10.1255. Review.

PMID:
18823221
12.

Current and future anti-HER2 therapy in breast cancer.

Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.

J BUON. 2013 Jan-Mar;18(1):4-16. Review.

PMID:
23613383
13.

An overview of HER-targeted therapy with lapatinib in breast cancer.

McArthur H.

Adv Ther. 2009 Mar;26(3):263-71. doi: 10.1007/s12325-009-0012-y. Epub 2009 Mar 27. Review.

PMID:
19365626
14.

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.

Larsen PB, Kümler I, Nielsen DL.

Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5. Review.

PMID:
23481218
15.

Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

Amir E, Ocaña A, Seruga B, Freedman O, Clemons M.

Cancer Treat Rev. 2010 Aug;36(5):410-5. doi: 10.1016/j.ctrv.2009.12.012. Epub 2010 Jan 25. Review.

PMID:
20100635
16.

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

Constantinidou A, Smith I.

Breast. 2011 Oct;20 Suppl 3:S158-61. doi: 10.1016/S0960-9776(11)70316-2. Review.

PMID:
22015286
17.

Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review.

Yip AY, Tse LA, Ong EY, Chow LW.

Anticancer Drugs. 2010 Jun;21(5):487-93. doi: 10.1097/CAD.0b013e3283388eaf. Review.

PMID:
20220514
18.

Lapatinib: a sword with two edges.

Kopper L.

Pathol Oncol Res. 2008 Mar;14(1):1-8. doi: 10.1007/s12253-008-9018-z. Epub 2008 Apr 12. Review.

PMID:
18409020
19.

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP.

Clin Cancer Res. 2009 Feb 15;15(4):1452-9. doi: 10.1158/1078-0432.CCR-08-1080.

20.

Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.

Guarneri V.

Expert Rev Anticancer Ther. 2009 Nov;9(11):1549-57. doi: 10.1586/era.09.124. Review.

PMID:
19895239

Supplemental Content

Support Center